Tag:

Pradaxa

Latest Headlines

Latest Headlines

Breakthrough anti-anticoagulants from Boehringer, Portola post stellar PhIII data

Portola Pharmaceuticals has laid out the last batch of Phase III data on its "breakthrough" anti-anticoagulant andexanet alfa, filling in the numbers that will be reviewed by regulators considering the biotech's upcoming pitch for marketing approval. And right alongside that announcement comes the latest numbers from Boehringer Ingelheim's breakthrough program for idarucizumab, which is already under review as an antidote to its blockbuster Pradaxa.

Boehringer takes pole position with its 'breakthrough' anti-anticoagulant

Boehringer Ingelheim submitted U.S., European and Canadian applications for an antidote to its own Pradaxa, leading the way among companies developing treatments that reverse the effects of blockbuster next-generation anticoagulants.

Daiichi's Savaysa goes up against next-gen anticoagulant trio in heated market race

What's long been a three-horse race just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter Savaysa. With the FDA's Thursday blessing, the drug will now face down a new-age anticoagulant trifecta that's been duking it out in the marketplace for a while now.

Pfizer, Bayer and Boehringer meds win backing from U.K. cost agency

This week, the U.K. National Institute for Health and Care Excellence blessed Pfizer's kidney cancer treatment Inlyta, changed its mind in support of Bayer's prostate cancer therapy Xofigo, and backed Boehringer Ingelheim's anticoagulant Pradaxa for blood clots in the legs and lungs.

Boehringer Ingelheim keeps rolling out data in support of anticoagulant Pradaxa

The safety message on Boehringer Ingelheim's key product, Pradaxa, has been mixed. But the German drugmaker has rolled out some new studies that show its effectiveness, as well as some promising data about the antidote being developed to treat serious bleeding in Pradaxa patients.

A tale of two studies: Prescribe Pradaxa 'with caution'? Or rely on FDA's safety backing?

One drug. Two new safety studies promoted on the same day. Two different conclusions. That's the situation with Pradaxa, the Boehringer Ingelheim anticoagulant that's drawn scrutiny for reports of serious bleeding--and prompted safety reviews in the U.S. and EU

Boehringer gets NICE nod for Pradaxa for DVT/PE in U.K.

Boehringer Ingelheim has completed a trifecta of approvals for its blood thinner Pradaxa for deep vein thrombosis and pulmonary embolism. The U.K. cost watchdog NICE has now given it a thumbs up after the FDA and the European regulators did the same thing this year.

BMJ targets Pradaxa safety, scolding Boehringer, FDA and EMA alike

The BMJ has set off a kerfuffle--and a Twitter campaign--over the safety of Boehringer Ingelheim's blockbuster anticoagulant Pradaxa.

Boehringer bags a 'breakthrough' tag for its Pradaxa antidote

German giant Boehringer Ingelheim is racing to the market with an antidote to its blockbuster blood-thinner Pradaxa, securing the FDA's coveted breakthrough therapy designation for its in-development treatment.

Boehringer scores European DVT/PE nod for market-trailer Pradaxa

In keeping with the FDA's recent approval, the European Commission has green-lighted Boehringer Ingelheim's clot-fighter Pradaxa to treat and prevent the recurrence of deep vein thrombrosis and pulmonary embolism, a nod that will boost Pradaxa as it battles it out in the anticoagulant market.